Last reviewed · How we verify
Thioguanine (thioguanine)
Thioguanine is a small molecule drug that targets Prostaglandin G/H synthase 1. It was originally developed by ASPEN GLOBAL INC and is currently owned by Waylis Therap. Thioguanine is a thioguanine drug class medication that was FDA approved in 1966 for the treatment of Acute myeloid leukemia. It has a half-life of 24.35 hours and bioavailability of 30%. Thioguanine is off-patent, meaning it is no longer protected by patents and can be manufactured by generic manufacturers.
At a glance
| Generic name | thioguanine |
|---|---|
| Also known as | tioguanine |
| Sponsor | Waylis |
| Drug class | thioguanine |
| Target | Prostaglandin G/H synthase 1 |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1966 |
Approved indications
- Acute myeloid leukemia, disease
Common side effects
- myelosuppression
- pancytopenia
- hyperuricemia
- nausea
- vomiting
- anorexia
- stomatitis
- intestinal necrosis
- perforation
- hepatic veno-occlusive disease
- portal hypertension
- splenomegaly
Key clinical trials
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE2)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (PHASE2)
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (PHASE3)
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (PHASE3)
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |